ScholarLens Back to search
2013•LeukemiaOpen access

Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab

Anna Maria Fink, Sebastian Böttcher, Matthias Ritgen, Kirsten Fischer, Natali Pflug, Barbara Eichhorst, C-M Wendtner, Dirk Winkler, Andreas Bühler, Thorsten Zenz, Peter Staib, Jiřı́ Mayer, M. Hensel, Georg Hopfinger, Michael Wenger, Günter Fingerle‐Rowson, Hartmut Döhner, Michael Kneba, Stephan Stilgenbauer, Robert Busch, Michael Hallek

Open full text 37 citations

Abstract

Chemoimmunotherapies like the combination of fludarabine, cyclophosphamide, and rituximab (FCR) achieve response rates as high as 95% in patients with previously untreated chronic lymphocytic leukemia (CLL). 1 Further improvements in clinical outcome will therefore mainly depend on attaining more durable remissions in those responders who suffer an early relapse. In general, progression of disease within 24 months after intensive chemoimmunotherapy is regarded as unsatisfactory 2 and might be associated with a shortened overall survival (OS). 3

Open-access reader

About this research paper

What this paper is about

Chemoimmunotherapies like the combination of fludarabine, cyclophosphamide, and rituximab (FCR) achieve response rates as high as 95% in patients with previously untreated chronic lymphocytic leukemia (CLL). 1 Further improvements in clinical outcome will therefore mainly depend on attaining more durable remissions in those responders who suffer an early relapse. In general, progression of disease within 24 months after intensive chemoimmunotherapy is regarded as unsatisfactory 2 and might be associated with a shortened overall survival (OS). 3

Why it matters

OpenAlex reports 37 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Chemoimmunotherapies like the combination of fludarabine, cyclophosphamide, and rituximab (FCR) achieve response rates as high as 95% in patients with previously untreated chronic lymphocytic leukemia (CLL). 1 Further improvements in clinical outcome will therefore mainly depend on attaining more durable remissions in those responders who suffer an early relapse. In general, progression of disease within 24 months after intensive chemoimmunotherapy is regarded as unsatisfactory 2 and might be associated with a shortened overall survival (OS). 3

Key concepts: Chemoimmunotherapy, Fludarabine, Rituximab, Cyclophosphamide, Medicine, Chronic lymphocytic leukemia, Oncology, Internal medicine

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab — Research Paper | ScholarLens